A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue

Vladimir Tolmachev, Irina Velikyan, Mattias Sandström, Anna Orlova

Research output: Contribution to journalArticlepeer-review

76 Citations (Scopus)

Abstract

Purpose: Overexpression of HER2 receptors is a prognostic and predictive biomarker in breast cancer and a number of other malignancies. Radionuclide molecular imaging of HER2 overexpression may influence patient management making treatment more personalized. Earlier, 111In-DOTA-Z HER2:342-pep2 (ABY-002) Affibody molecule demonstrated excellent imaging of HER2-expressing xeno-grafts in mice shortly after injection. The use of the positron-emitting nuclide 68Ga instead of 111In might increase both the sensitivity of HER2 imaging and accuracy of expression quantification. The goal of this study was to prepare and characterize 68Ga-labelled ABY-002. Methods: 68Ga labelling of ABY-002 was optimized. In vitro cell binding and procession of 68Ga-ABY-002 was evaluated. Biodistribution and tumour targeting of 68Ga-ABY-002 and 111In-ABY-002 was compared in vivo by paired-label experiments. Results: ABY-002 was incubated with 68Ga at 90°C for 10 min resulting in a radiochemical labelling yield of over 95%. Capacity for specific binding to HER2-expressing cells was retained. In vivo, both 68Ga-ABY-002 and 111In-ABY-002 demonstrated specific targeting of SKOV-3 xenografts and high-contrast imaging. Background radioactivity in blood, lungs, gastrointestinal tract and muscle fell more rapidly for 68Ga-ABY-002 compared with 111In-ABY-002 favouring imaging shortly after injection. For 68Ga-ABY-002, a tumour uptake of 12.4±3.8%ID/g and a tumour to blood ratio of 31±13 were achieved at 2 h post-injection. Conclusion: 68Ga-ABY-002 is easy to label and provides high-contrast imaging within 2 h after injection. This makes it a promising candidate for clinical molecular imaging of HER2 expression in malignant tumours.

Original languageEnglish
Pages (from-to)1356-1367
Number of pages12
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 2010
Externally publishedYes

Keywords

  • Ga
  • Affibody molecule
  • HER2
  • Molecular imaging
  • Tumour targeting

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'A HER2-binding Affibody molecule labelled with <sup>68</sup>Ga for PET imaging: Direct in vivo comparison with the <sup>111</sup>In-labelled analogue'. Together they form a unique fingerprint.

Cite this